TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3140327

Group type: EXPERIMENTAL
Intervention: Metaproterenol solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromolyn solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 8
Study: 30376407

Group type: EXPERIMENTAL
Intervention: School-based intervention program promoting personal hygiene
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 143
Study: 28567696

Group type: EXPERIMENTAL
Intervention: Stress condition of the Maastricht Acute Stress Test (MAST)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No stress condition of the Maastricht Acute Stress Test (MAST)
Number of subjects: 82
Study: 26223254

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm) alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Short implants (8 mm) combined with osteotome sinus floor elevation (OSFE)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard implants (10 mm) combined with osteotome sinus floor elevation (OSFE)
Number of subjects: 150
Study: 23532242

Group type: EXPERIMENTAL
Intervention: Erythromycin (400 mg, twice daily)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 20554506

Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT) using Q-switched Nd:YLF laser, wavelength 527 nm, t=1.7 μs, energy 100-370 μJ, spot diameter 200 μm, pulse repetition rate 100 Hz
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selective retina therapy (SRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment initially)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cross-over group treated with SRT after initial control
Number of subjects: 30
Study: 18929279

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg/kg (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg/kg (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.2 mg/kg (Group C)
Number of subjects: 75
Study: 16369133

Group type: EXPERIMENTAL
Intervention: BIS-guided group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 14652364

Group type: EXPERIMENTAL
Intervention: 20 mg elemental iron with 1 mg riboflavin
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: 20 mg elemental zinc with 1 mg riboflavin
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: 20 mg iron and 20 mg zinc with 1 mg riboflavin
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Micronutrient mix (MM) containing 20 mg iron, 20 mg zinc, 1 mg riboflavin along with other minerals and vitamins
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control treatment, 1 mg riboflavin only
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Iron + zinc supplementation
Number of subjects: 799
Study: 11020543

Group type: EXPERIMENTAL
Intervention: Benzodiazepines prescribed (70%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Depressive disorders
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irritability as a symptom
Number of subjects: 50
Study: 8618584

Group type: EXPERIMENTAL
Intervention: Intensive primary care intervention (close follow-up by a nurse and primary care physician for six months)
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1396
Study: 1452950

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement containing protein (20.4 g), mineral salts (Ca: 0.525 g), and vitamins A = 750 IU; D3 = 25 IU, 250 ml/day for a mean of 38 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group received the same supplement dose but with no protein, 250 ml/day for a mean of 38 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Protein-supplemented group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 6362490

Group type: EXPERIMENTAL
Intervention: 0.2 mg of epinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.3 mg of epinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 mg of phenylephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 mg of phenylephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epinephrine and phenylephrine (at equipotent doses)
Number of subjects: 50
Study: 30275690

Group type: EXPERIMENTAL
Intervention: GLY 25 µg twice daily
Number of subjects: 2379

Group type: EXPERIMENTAL
Intervention: GLY 50 µg twice daily
Number of subjects: 2379

Group type: COMPARATOR
Intervention: TIO 18 µg once daily
Number of subjects: 2379
Study: 27417981

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 0
Study: 24266596

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of 1000 units of human pasteurized C1‐INH concentrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1000 units of human pasteurized C1‐INH concentrate
Number of subjects: 24
Study: 22866996

Group type: EXPERIMENTAL
Intervention: Yoga Nidra relaxation preceded by Hatha yoga (YR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Yoga Nidra relaxation only (R)
Number of subjects: 20
Study: 20117960

Group type: EXPERIMENTAL
Intervention: Hypo-osmotic saline drops (280mmol/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hyper-osmotic saline drops (380mmol/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hypo-osmotic saline drops (280mmol/kg) and Hyper-osmotic saline drops (380mmol/kg)
Number of subjects: 15
Study: 18310627

Group type: EXPERIMENTAL
Intervention: Synera patch and saline infiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch and 2% lidocaine infiltration
Number of subjects: 0
Study: 15808659

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg per dose during the anhepatic period and two doses every other day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: No thymoglobulin (control group)
Number of subjects: 22
Study: 14652238

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Serum 25-(OH) vitamin D levels
Number of subjects: 803

Group type: COMPARATOR
Intervention: VDR polymorphisms
Number of subjects: 803
Study: 10653826

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 3522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3522
Study: 9015776

Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy (IT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy (IT) with grass pollen extracts
Number of subjects: 31
Study: 1615900

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) of 1757 kJ/d for 1-2 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supplemental low-calorie diet (LCD) of 3515-5021 kJ/d for 1-2 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Supplemental low-calorie diet (LCD)
Number of subjects: 45
Study: 6423045

Group type: EXPERIMENTAL
Intervention: Practical lunchtime demonstrations (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Videotape education (group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional diet sheet instruction (group 1)
Number of subjects: 40
Study: 29991952

Group type: EXPERIMENTAL
Intervention: Liuzijue exercise combined with elastic band resistance exercise (LEG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Liuzijue exercise (LG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 25491541

Group type: EXPERIMENTAL
Intervention: Combination of acupoints BL23 and KI3
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acupoint BL23
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acupoint SP6
Number of subjects: 58
Study: 25211605

Group type: EXPERIMENTAL
Intervention: Human Skin Allograft (HSA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Human Fibroblast-Derived Dermal Skin (HFDS)
Number of subjects: 23
Study: 22619396

Group type: COMPARATOR
Intervention: Single context condition
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multiple context condition
Number of subjects: 52
Study: 20016147

Group type: EXPERIMENTAL
Intervention: 20 g of stabilized rice bran once daily for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 28
Study: 17483102

Group type: EXPERIMENTAL
Intervention: Empowerment-oriented group homes
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Independent apartments
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Group home
Number of subjects: 112
Study: 16305864

Group type: EXPERIMENTAL
Intervention: Single-layer closure with suction drain
Number of subjects: 78

Group type: COMPARATOR
Intervention: Multiple-layer closure
Number of subjects: 78
Study: 11915458

Group type: EXPERIMENTAL
Intervention: Dynamization of interlocking nails
Number of subjects: 50

Group type: COMPARATOR
Intervention: No dynamization
Number of subjects: 50
Study: 11075561

Group type: EXPERIMENTAL
Intervention: hANP (0.1 microgram.kg‐1.min‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no hANP infusion)
Number of subjects: 13
Study: 9147122

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF2) dentifrice
Number of subjects: 246

Group type: COMPARATOR
Intervention: NaF dentifrice
Number of subjects: 246
Study: 1315827

Group type: EXPERIMENTAL
Intervention: Low-sodium, low-fat/high-fibre diet (less than 60 mmol sodium/day; 30% fat energy; P:S ratio = 1; 30-50 g fibre/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Low-sodium, normal-fat/normal-fibre diet (less than 60 mmol sodium/day; 40% fat energy; P:S ratio = 0.3; 15 g fibre/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Low-sodium, low-fat/high-fibre diet
Number of subjects: 95

Group type: COMPARATOR
Intervention: Low-sodium, normal-fat/normal-fibre diet
Number of subjects: 95
Study: 3889076

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/d for days 1-6, 360 mg/d for days 7-12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/d for days 1-6, 480 mg/d for days 7-12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verapamil (combined with quinidine 750 mg/d for part III)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quinidine (750 mg/d for part III)
Number of subjects: 30
Study: 31041591

Group type: EXPERIMENTAL
Intervention: Commercially available meal replacement product (2 servings/day) + other supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: New meal replacement (2 servings/day)
Number of subjects: 0
Study: 29662303

Group type: EXPERIMENTAL
Intervention: Sterimar Mn nasal spray (4 puffs/day) for 5 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 26372606

Group type: EXPERIMENTAL
Intervention: 50 g sucrose in 500 mL water
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 g sucrose in 500 mL water
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0 g sucrose (control)
Number of subjects: 90
Study: 24758775

Group type: EXPERIMENTAL
Intervention: Ultrasound and electrical stimulation through the needle
Number of subjects: 437

Group type: COMPARATOR
Intervention: Ultrasound alone
Number of subjects: 437
Study: 22307942

Group type: EXPERIMENTAL
Intervention: OCR 200 mg + MTX
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: OCR 500 mg + MTX
Number of subjects: 613

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 613
Study: 20102728

Group type: COMPARATOR
Intervention: Smelling chocolate (n=6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eating chocolate (n=6)
Number of subjects: 12
Study: 17438216

Group type: EXPERIMENTAL
Intervention: Rotigotine 8 mg/24 hours
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Rotigotine 12 mg/24 hours
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 16123321

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 32
Study: 12183307

Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol based solution (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Handwashing with antiseptic soap (n=11)
Number of subjects: 23
Study: 10093648

Group type: EXPERIMENTAL
Intervention: TIVA (propofol/remifentanil)
Number of subjects: 105

Group type: COMPARATOR
Intervention: VOLATIL (sevoflurane/N2O)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Posterior fixation suture (faden-operation)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Other operations
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Recessions
Number of subjects: 105
Study: 7762503

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 1969402

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg twice daily (A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg twice daily (N)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study: 31437456

Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 20
Study: 31169651

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral subcostal TAP block with 20 ml of levobupivacaine 0.375% and epinephrine 5 μg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline with epinephrine 5 μg/ml (Control)
Number of subjects: 60
Study: 27233381

Group type: EXPERIMENTAL
Intervention: Higher urine potassium excretion (measured as 1-SD increase in baseline urine potassium level)
Number of subjects: 812
Study: 26410153

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration and preoperative oral ketorolac
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine plus buccal and lingual infiltration
Number of subjects: 150
Study: 23482074

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) turned on
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) turned off
Number of subjects: 63
Study: 21677021

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) targeting lower limb muscles, twice a week for 10 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care plus attention and social program, once a week for 10 weeks
Number of subjects: 71
Study: 18774342

Group type: EXPERIMENTAL
Intervention: Online mind-body self-care intervention (n = 41)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waiting list comparison group (n = 37)
Number of subjects: 78
Study: 17091411

Group type: EXPERIMENTAL
Intervention: Group intervention program consisting of education, ergonomics, exercises, pain management, advice for daily life movement, pelvic belt/crutches, and information about delivery (n=275)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Control group with no treatment (n=285)
Number of subjects: 569
Study: 14742987

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (AmBd)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 100
Study: 11311619

Group type: EXPERIMENTAL
Intervention: PMMA IOL
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Soft acrylic IOL
Number of subjects: 137

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 137
Study: 9461266

Group type: EXPERIMENTAL
Intervention: Cefuroxime (single shot)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Amoxycillin-netilmicin (4-day regimen)
Number of subjects: 1009
Study: 7929709

Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - Tulving and Colotla measure
Number of subjects: 13

Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - recall from recency measure
Number of subjects: 13

Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - secondary memory (SM) measures
Number of subjects: 13

Group type: COMPARATOR
Intervention: California Verbal Learning Test (CVLT) - clustering words by taxonomic category
Number of subjects: 13
Study: 3283622

Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 321

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 321
Study: 29991131

Group type: EXPERIMENTAL
Intervention: Music therapy (singing group)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Lyric reading group
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 298
Study: 28456851

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (n = 107)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ruxolitinib crossover (n = 97)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Interferon as BAT (n = 13)
Number of subjects: 107
Study: 25758457

Group type: EXPERIMENTAL
Intervention: Removable intraoral vibrational device (AcceleDent; n = 29)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Identical nonfunctional (sham) device (n = 25)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fixed appliances only (n = 27)
Number of subjects: 81
Study: 23845666

Group type: EXPERIMENTAL
Intervention: SIMS‐Ajust
Number of subjects: 137

Group type: COMPARATOR
Intervention: TVT‐O
Number of subjects: 137
Study: 20805754

Group type: EXPERIMENTAL
Intervention: Propofol/dexmedetomidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol/fentanyl
Number of subjects: 50
Study: 19043908

Group type: EXPERIMENTAL
Intervention: Integrated group program involving social group work intervention and Chinese medicine therapeutics
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 28
Study: 16390558

Group type: EXPERIMENTAL
Intervention: 4% albumin (colloid priming)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pure crystalloid priming solution
Number of subjects: 22
Study: 12804730

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Type 1C AAM
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Type 1A AAM
Number of subjects: 409
Study: 10780867

Group type: EXPERIMENTAL
Intervention: Alendronate 2.5, 5, or 10 mg/day for 1 year
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 8721381

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 10 days (first trial)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 21 days (second trial)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Placebo (control group in both trials)
Number of subjects: 629
Study: 1815000

Group type: EXPERIMENTAL
Intervention: Normal add progressive addition lenses (PALs)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Overplussed add progressive addition lenses (PALs)
Number of subjects: 29
Study: 6689277

Group type: EXPERIMENTAL
Intervention: Mepindolol alone (10 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone (25 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mepindolol and Hydrochlorothiazide in combination (Tenesor)
Number of subjects: 5
Study: 31545480

Group type: EXPERIMENTAL
Intervention: hsa_circ_0137606
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-grade BC
Number of subjects: 0
Study: 30028922

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard treatment protocol (control group)
Number of subjects: 68
Study: 26589633

Group type: EXPERIMENTAL
Intervention: 4-monthly BoNT-A injections
Number of subjects: 42

Group type: COMPARATOR
Intervention: 12-monthly BoNT-A injections
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for children with hemiplegia
Number of subjects: 42
Study: 25456561

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to motivate physical activity over 12 months
Number of subjects: 242

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 242
Study: 22580592

Group type: EXPERIMENTAL
Intervention: Modified Early Warning Score (MEWS) calculated by anaesthetists before and after surgical procedure.
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Control group (patients admitted before MEWS application).
Number of subjects: 1082
Study: 20831131

Group type: COMPARATOR
Intervention: Conventional glass ionomer cement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Adhesive resin cement
Number of subjects: 45
Study: 18622315

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied at the time of tonsillectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 70
Study: 16564941

Group type: EXPERIMENTAL
Intervention: Glucose in dialysis fluid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no glucose in dialysis fluid)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Glucose in dialysis fluid (diabetic subgroup)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no glucose in dialysis fluid, diabetic subgroup)
Number of subjects: 44
Study: 12575969

Group type: EXPERIMENTAL
Intervention: Chelation therapy with EDTA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10588313

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 5 days
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 10 days
Number of subjects: 805

Group type: COMPARATOR
Intervention: Clarithromycin 250 mg bd for 10 days
Number of subjects: 805
Study: 8723851

Group type: EXPERIMENTAL
Intervention: Ulinastatin (6000 U.kg‐1 before CPB and before declamping of aorta)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated (Group I)
Number of subjects: 22